Create a narrative

Exagen Community

NasdaqGM:XGN Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

Expanding Test Menu And Territories Will Unlock Precision Diagnostics Demand

Key Takeaways Expanding test offerings, sales reach, and clinical validation position Exagen for significant market growth, margin improvement, and broader reimbursement. Strategic biopharma collaborations, disciplined operations, and digital integration support scalable, high-margin revenue and sustained earnings growth.

US$11.17

FV

13.4% undervalued

15.46%

Revenue growth p.a.

0

0

3

6 days ago